Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy

Cardiovascular Research

Volumn 105, Issue 2, 2015, Pages 160-170

  Moc, Courtney ^a   Taylor, Amy E ^a   Chesini, Gino P ^a   Zambrano, Cristina M ^a   Barlow, Melissa S ^a   Zhang, Xiaoxue ^a   Gustafsson, Åsa B ^a   Purcell, Nicole H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Akt; Hypertrophy; Mouse model; PH domain leucine rich repeat protein phosphatase; PHLPP

Indexed keywords

PH DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; NUCLEAR PROTEIN; PHLPP PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL DEATH; COCULTURE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FORCED SWIM TEST; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HEART FUNCTION; HEART SIZE; HEART VENTRICLE HYPERTROPHY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; MUSCLE CELL; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA ISOLATION; SIGNAL TRANSDUCTION; WILD TYPE MOUSE; ANIMAL; DEFICIENCY; GENETICS; HEART; HEART MUSCLE; HEART MUSCLE CELL; HYPERTROPHY; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION;

ANIMALS; HEART; HYPERTROPHY; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84922460697     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu243     Document Type: Article

References (58)

1. Kemi OJ, Ceci M, Wisloff U, Grimaldi S, Gallo P, Smith GL, Condorelli G, Ellingsen O. Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy. J Cell Physiol 2008;214:316-321.
2. Catalucci D, Latronico MV, Ellingsen O, Condorelli G. Physiological myocardial hypertrophy: how and why? Front Biosci 2008;13:312-324.
3. Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol 2013;14:38-48.
4. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007;49: 962-970.
5. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 2010;122:2727-2735.
6. van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013;123:37-45.
7. Sadoshima J, Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 1997;59:551-571.
8. Sussman MA, Volkers M, Fischer K, Bailey B, Cottage CT, Din S, Gude N, Avitabile D, Alvarez R, Sundararaman B, Quijada P, Mason M, Konstandin MH, Malhowski A, Cheng Z, Khan M, McGregor M. Myocardial AKT: the omnipresent nexus. Physiol Rev 2011;91:1023-1070.
9. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-537.
10. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600.
11. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002;99:12333-12338.
12. DeBosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M, Muslin AJ. Akt1 is required for physiological cardiac growth. Circulation 2006;113:2097-2104.
13. Shioi T, McMullen JR, Kang PM, Douglas PS, Obata T, Franke TF, Cantley LC, Izumo S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 2002;22: 2799-2809.
14. 2+ cycling by direct phosphorylation of phospholamban at Thr17. J Biol Chem 2009;284: 28180-28187.
15. Latronico MVG, Costinean S, Lavitrano ML, Peschle C, Condorelli G. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann N Y Acad Sci 2004;1015: 250-260.
16. Shiojima I, Schiekofer S, Schneider JG, Belisle K, Sato K, Andrassy M, Galasso G, Walsh K. Short-term Akt activation in cardiac muscle cells improves contractile function in failing hearts. Am J Path 2012;181:1969-1976.
17. Schiekofer S, Belisle K, Galasso G, Schneider JG, Boehm BO, Burster T, Schmitz G, Walsh K. Angiogenic-regulatory network revealed by molecular profiling heart tissue following Akt1 induction in endothelial cells. Angiogenesis 2008;11:289-299.
18. Kitamura T, Asai N, Enomoto A, Maeda K, Kato T, Ishida M, Jiang P, Watanabe T, Usukura J, Kondo T, Costantini F, Murohara T, Takahashi M. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol 2008;10:329-337.
19. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51.
20. Newton AC, Trotman LC. Turning Off AKT:PHLPPasadrug target. Annu Rev Pharmacol Toxicol 2014;54:537-558.
21. Mullonkal CJ, Toledo-Pereyra LH. Akt in ischemia and reperfusion. J Invest Surg 2007;20: 195-203.
22. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-2208.
23. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, Birnbaum MJ. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005;25: 1869-1878.
24. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, Sundararajan D, Chen WS, Crawford SE, Coleman KG, Hay N. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-1365.
25. Gao T, Furnari F, Newton AC. PHLPP:aphosphatase that directly dephosphorylatesAkt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13-24.
26. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007;25:917-931.
27. Shimizu K, Okada M, Nagai K, Fukada Y. Suprachiasmatic nucleus circadian oscillatory protein, a novel binding partner of K-Ras in the membrane rafts, negatively regulates MAPK pathway. J Biol Chem 2003;278:14920-14925.
28. Miyamoto S, Purcell NH, Smith JM, Gao T, Whittaker R, Huang K, Castillo R, Glembotski CC, Sussman MA, Newton AC, Brown JH. PHLPP-1 negatively regulates Akt activity and survival in the heart. Circ Res 2010;107:476-484.
29. Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem 2008;283:6300-6311.
30. Liu J, Stevens PD, Li X, Schmidt MD, Gao T. PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 2011;31:4917-4927.
31. Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, Pardee AB. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 2010;38:512-523.
32. McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S. The insulin-like growth factor 1 re-ceptorinduces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 2004;279:4782-4793.
33. Ceci M, Gallo P, Santonastasi M, Grimaldi S, Latronico MV, Pitisci A, Missol-Kolka E, Scimia MC, Catalucci D, Hilfiker-Kleiner D, Condorelli G. Cardiac-specific overexpres-sion of E40K active Akt prevents pressure overload-induced heart failure in mice by increasing angiogenesis and reducing apoptosis. Cell Death Differ 2007;14:1060-1062.
34. Kim YK, Kim SJ, Yatani A, Huang Y, Castelli G, Vatner DE, Liu J, Zhang Q, Diaz G, Zieba R, Thaisz J, Drusco A, Croce C, Sadoshima J, Condorelli G, Vatner SF. Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt. J Biol Chem 2003;278:47622-47628.
35. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005;115:2108-2118.
36. Tsujita Y, Muraski J, Shiraishi I, Kato T, Kajstura J, Anversa P, Sussman MA. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 2006;103:11946-11951.
37. Rota M, Boni A, Urbanek K, Padin-Iruegas ME, Kajstura TJ, Fiore G, Kubo H, Sonnenblick EH, Musso E, Houser SR, Leri A, Sussman MA, Anversa P. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ Res 2005;97: 1332-1341.
38. 2+ channel activity by modulating Cavalpha1 protein stability. J Cell Biol 2009;184:923-933.
39. Chen B, Van Winkle JA, Lyden PD, Brown JH, Purcell NH. PHLPP1 gene deletion protects the brain from ischemic injury. J Cereb Blood Flow Metab 2013;33:196-204.
40. Maillet M, Purcell NH, Sargent MA, York AJ, Bueno OF, Molkentin JD. DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility. J Biol Chem 2008;283: 31246-31255.
41. Purcell NH, Wilkins BJ, York A, Saba-El-Leil MK, Meloche S, Robbins J, Molkentin JD. Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci USA 2007;104: 14074-14079.
42. Dusaban SS, Purcell NH, Rockenstein E, Masliah E, Cho MK, Smrcka AV, Brown JH. Phospholipase C{varepsilon} links G protein-coupled receptor activation to inflammatory astrocytic responses. Proc Natl Acad Sci USA 2013;110:3609-3614.
43. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, Gude NA, Thistlethwaite PA, Sussman MA, Gottlieb RA, Gustafsson AB. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater uscept-ibility to stress-induced myocardial injury in adult mice. Circulation 2010;121:675-683.
44. Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, Murn J, Navin N, Atwal GS, Sander C, Gerald WL, Cordon-Cardo C, Newton AC, Carver BS, Trotman LC. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011;20:173-186.
45. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996;15: 6541-6551.
46. Kim J, Wende AR, Sena S, Theobald HA, Soto J, Sloan C, Wayment BE, Litwin SE, Holzenberger M, LeRoith D, Abel ED. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol Endo 2008;22:2531-2543.
47. Shiojima I, Walsh K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 2006;20:3347-3365.
48. Park M, Vatner SF, Yan L, Gao S, Yoon S, Lee GJ, Xie LH, Kitsis RN, Vatner DE. Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload. Basic Res Cardiol 2013;108:324.
49. Cittadini A, Monti MG, Iaccarino G, Di Rella F, Tsichlis PN, Di Gianni A, Stromer H, Sorriento D, Peschle C, Trimarco B, Sacca L, Condorelli G. Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular calcium handling. Gene Ther 2006;13:8-19.
50. Hua Y, Zhang Y, Ceylan-Isik AF, Wold LE, Nunn JM, Ren J. Chronic Akt activation accentuates aging-induced cardiac hypertrophy and myocardial contractile dysfunction: role of autophagy. Basic Res Cardiol 2011;106:1173-1191.
51. Cook SA, Matsui T, Li L, Rosenzweig A. Transcriptional effects of chronic Akt activation in the heart. J Biol Chem 2002;277:22528-22533.
52. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008;415:333-344.
53. Yamashita K, Kajstura J, Discher DJ, Wasserlauf BJ, Bishopric NH, Anversa P, Webster KA. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpressing insulin-like growth factor-1. Circ Res 2001;88:609-614.
54. Jackson TC, Verrier JD, Semple-Rowland S, Kumar A, Foster TC. PHLPP1 splice variants differentially regulate AKT and PKCalpha signaling in hippocampal neurons: characterization of PHLPP proteins in the adult hippocampus. J Neurochem 2010; 115:941-955.
55. Li X, Stevens PD, Liu J, Yang H, Wang W, Wang C, Zeng Z, Schmidt MD, Yang M, Lee EY, Gao T. PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell mo-tility and prevents tumor progression in mice. Gastroenterology 2014;146:1301-1312 e1301-1310.
56. Ackah E, Yu J, Zoellner S, Iwakiri Y, Skurk C, Shibata R, Ouchi N, Easton RM, Galasso G, Birnbaum MJ, Walsh K, Sessa WC. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest 2005;115:2119-2127.
57. Giordano FJ, Gerber HP, Williams SP, Van Bruggen N, Bunting S, Ruiz-Lozano P, Gu Y, Nath AK, Huang Y, Hickey R, Dalton N, Peterson KL, Ross J Jr, Chien KR, Ferrara N. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci USA 2001;98:5780-5785.
58. Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 2006;47: 887-893.